Huang C L, Brassil D, Rozzell M, Schellhammer P F, Wright G L
Department of Microbiology, Eastern Virginia Medical School, Norfolk 23501.
Prostate. 1993;23(3):201-12. doi: 10.1002/pros.2990230303.
Serum prostate secretory protein (PSP) levels were measured in 49 patients with benign prostatic hyperplasia (BPH), 144 patients with various stages of prostatic carcinoma (CaP), and 82 CaP patients who were followed serially. PSP values were compared with serum levels of prostate specific antigen (PSA) and prostatic acid phosphatase (PAP). In the BPH group, PSP was elevated (> 10 ng/ml) in 41% of patients, whereas PSA (> 4 ng/ml) and PAP (> 3.3 ng/ml) were elevated in 39% and 23% of the cases, respectively. PSP levels were elevated in 48% of the CaP pretreatment specimens, compared to 79% for PSA and 40% for PAP. PSP levels in cancer patients who had intracapsular disease were about two to three times higher than those observed for PAP. PSP was found to be the only marker elevated in eight (6%) pretreatment CaP patient serum specimens, while PAP was never found to be elevated when PSA was normal. PSP serum concentrations correlated with the clinical course of the disease in 79% of patients, compared with 90% for PSA and 66% for PAP. In certain patients, monitored over time, disease correlation was reflected in serum values with only a single biomarker, i.e., 1% with PAP, 8% with PSP, and 10% with PSA. This study has shown that PSP is a less sensitive serum biomarker than PSA, but more sensitive than PAP for detection and monitoring the early stages of prostate cancer. This suggests that PSP as a biomarker may be a useful adjunct for the management of a subpopulation of low-stage and -grade CaP.
对49例良性前列腺增生（BPH）患者、144例不同前列腺癌（CaP）分期患者以及82例接受连续随访的CaP患者测定了血清前列腺分泌蛋白（PSP）水平。将PSP值与前列腺特异性抗原（PSA）和前列腺酸性磷酸酶（PAP）的血清水平进行比较。在BPH组中，41%的患者PSP升高（>10 ng/ml），而PSA（>4 ng/ml）和PAP（>3.3 ng/ml）升高的病例分别为39%和23%。CaP预处理标本中48%的PSP水平升高，而PSA为79%，PAP为40%。患有包膜内疾病的癌症患者的PSP水平比PAP观察值高约两到三倍。发现PSP是8例（6%）CaP预处理患者血清标本中唯一升高的标志物，而当PSA正常时，从未发现PAP升高。79%的患者PSP血清浓度与疾病临床进程相关，而PSA为90%，PAP为66%。在某些随时间监测的患者中，疾病相关性仅通过单一生物标志物反映在血清值中，即1%通过PAP、8%通过PSP、10%通过PSA。本研究表明，对于前列腺癌早期的检测和监测，PSP是一种比PSA敏感性低但比PAP敏感性高的血清生物标志物。这表明PSP作为一种生物标志物可能是低分期和低分级CaP亚群管理的有用辅助手段。
